Paris-based BioTech startup EG 427 has raised €27 million in a Series B financing round to advance its innovative genetic medicines for chronic neurological diseases. The funding was co-led by Andera Partners and Bpifrance as part of the InnoBio investment strategy, with SCI Ventures and existing investors also participating. MTS Health Partners acted as the exclusive financial advisor for the transaction.
The fresh capital will propel the development of EG 427’s lead candidate, EG110A, a groundbreaking genetic therapy targeting neurogenic bladder dysfunction. This condition, which affects patients with spinal cord injuries and neurodegenerative diseases such as multiple sclerosis and Parkinson’s, currently lacks effective long-term treatment options.
“The successful closing of this financing round marks a significant milestone for EG 427. It brings the strong support of major institutional investors, reaffirming the potential of genetic medicine to address widespread chronic diseases,” said Philippe Chambon, MD, PhD, Chief Executive Officer of EG 427. “Our initial focus is on neuro-urology, a field that remains underserved despite its high healthcare costs. This funding enables us to advance our first program targeting bladder dysfunctions through its initial clinical trial.”
Founded in 2019 by a team of experienced researchers and clinicians, EG 427 is pioneering the use of non-replicating HSV-1 (nrHSV-1) vector technology to deliver highly targeted gene therapies. Unlike traditional treatments, EG110A aims to selectively silence key sensory neurons responsible for bladder muscle overactivity while preserving normal voiding function. This first-in-human study could pave the way for a new class of precision neurotherapeutics.
“EG 427’s platform has the potential to transform the landscape of genetic medicine by offering pinpoint delivery and local administration,” said Benoît Barteau, Investment Director at Bpifrance. “Its technology could enable repeated dosing and more cost-effective production compared to traditional viral vector approaches.”
The Series B funds will support a Phase 1b/2a clinical trial of EG110A in the U.S., with the goal of addressing a series of neglected neuro-urological disorders. Additionally, the financing will fuel EG 427’s broader pipeline expansion using its proprietary HERpes Modular Expression System (HERMES), which enables long-term, targeted gene therapy solutions for neurological conditions.
“EG 427 is at the forefront of a new era in neurotherapy,” said Raphaël Wisniewski, Partner at Andera Partners. “With its unique approach to genetic medicine, the company is well-positioned to disrupt existing treatment paradigms and improve the lives of millions of patients.”
As EG 427 moves forward with clinical trials and product development, its cutting-edge technology could redefine how chronic neurological diseases are treated, offering hope for patients worldwide.
